NovoCure Limited (NASDAQ:NVCR) COO Sells $33,775.21 in Stock

NovoCure Limited (NASDAQ:NVCRGet Free Report) COO Wilhelmus Cm Groenhuysen sold 2,107 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $16.03, for a total value of $33,775.21. Following the completion of the transaction, the chief operating officer now directly owns 252,452 shares of the company’s stock, valued at approximately $4,046,805.56. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Wilhelmus Cm Groenhuysen also recently made the following trade(s):

  • On Monday, March 4th, Wilhelmus Cm Groenhuysen sold 1,217 shares of NovoCure stock. The stock was sold at an average price of $16.01, for a total value of $19,484.17.

NovoCure Price Performance

Shares of NovoCure stock opened at $17.29 on Friday. NovoCure Limited has a one year low of $10.87 and a one year high of $83.60. The stock’s fifty day moving average is $14.81 and its 200 day moving average is $15.47. The stock has a market cap of $1.85 billion, a P/E ratio of -8.87 and a beta of 0.41. The company has a debt-to-equity ratio of 1.57, a quick ratio of 5.56 and a current ratio of 5.78.

NovoCure (NASDAQ:NVCRGet Free Report) last announced its earnings results on Thursday, February 22nd. The medical equipment provider reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.08. The company had revenue of $133.80 million for the quarter, compared to analysts’ expectations of $133.80 million. NovoCure had a negative return on equity of 51.63% and a negative net margin of 40.65%. NovoCure’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.36) EPS. Sell-side analysts anticipate that NovoCure Limited will post -1.74 earnings per share for the current year.

Analysts Set New Price Targets

NVCR has been the subject of several research reports. HC Wainwright increased their target price on NovoCure from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Wedbush restated a “neutral” rating and issued a $21.00 price target on shares of NovoCure in a research note on Monday, January 8th. Finally, Evercore ISI upped their price target on NovoCure from $14.00 to $15.00 and gave the stock an “in-line” rating in a research note on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Check Out Our Latest Stock Report on NovoCure

Institutional Investors Weigh In On NovoCure

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. raised its holdings in NovoCure by 3.3% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 5,222 shares of the medical equipment provider’s stock valued at $314,000 after acquiring an additional 165 shares during the period. Baird Financial Group Inc. grew its position in shares of NovoCure by 1.5% during the fourth quarter. Baird Financial Group Inc. now owns 16,061 shares of the medical equipment provider’s stock valued at $1,179,000 after purchasing an additional 230 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its position in shares of NovoCure by 1.3% during the fourth quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 23,400 shares of the medical equipment provider’s stock valued at $1,716,000 after purchasing an additional 300 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of NovoCure by 0.8% during the fourth quarter. Alliancebernstein L.P. now owns 44,523 shares of the medical equipment provider’s stock valued at $3,266,000 after purchasing an additional 355 shares in the last quarter. Finally, American International Group Inc. grew its position in shares of NovoCure by 26.9% during the second quarter. American International Group Inc. now owns 1,950 shares of the medical equipment provider’s stock valued at $81,000 after purchasing an additional 413 shares in the last quarter. 84.11% of the stock is owned by institutional investors.

About NovoCure

(Get Free Report)

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma.

Recommended Stories

Insider Buying and Selling by Quarter for NovoCure (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.